Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
NL REPORTS FOURTH QUARTER 2023 RESULTS
-
Kadant Declares Cash Dividend
-
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
-
Canon U.S.A., Inc. Recognized by Forbes as One of America's Best Midsize Employers in 2024
-
Havila Kystruten AS: Quarterly report for fourth quarter 2023 – corrections
-
Paycor Announces Offering of Common Stock by Selling Stockholders
-
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
-
Lytus Technologies Enters $326 Billion Data Center Market with Launch of Cutting-Edge Lytus Cloud Infrastructure Services
-
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
-
Supernus to Participate in Two Upcoming Investor Conferences
-
Acuity Brands to Announce Fiscal 2024 Second Quarter Results on April 3, 2024
-
IDT Corporation Reports Second Quarter Fiscal Year 2024 Results
-
AllSurplus to Conduct Online Auction of Surplus Equipment and Machinery for Leading Arms Manufacturer in U.S.
-
Intrepid Announces Fourth Quarter and Full-Year 2023 Results
-
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
-
Springbig to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
-
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
-
DraftKings Announces Jason Robins’ Participation in Upcoming Event
-
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
-
NL REPORTS FOURTH QUARTER 2023 RESULTS
-
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
-
ADT Announces Launch of Secondary Public Offering of Common Stock and Concurrent Share Repurchase
-
Greystone Housing Impact Investors LP Increases Line of Credit to $50 Million
-
Rush Street Interactive Announces Fourth Quarter and Full Year 2023 Results
-
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
-
NeoGames Announces Fourth Quarter and Full Year 2023 Results
-
KRONOS WORLDWIDE, INC. REPORTS FOURTH QUARTER 2023 RESULTS
-
Omega Flex, Inc. Announces Fourth Quarter 2023 Earnings
-
Nanobiotix to Present at Upcoming Investor Conferences in March
-
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
-
Oil-Dri Board of Directors Declares Quarterly Dividends
-
Cohen & Company Reports Fourth Quarter & Full Year 2023 Financial Results
-
GEN Restaurant Group, Inc. Announces Fourth Quarter 2023 Financial Results
-
Hudson Technologies Reports Fourth Quarter and Year End 2023 Results
-
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
-
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
-
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
-
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Sow Good to Hold Fourth Quarter and Full Year 2023 Conference Call on Friday, March 22, 2024 at 10:00 a.m. ET
-
Infinera Corporation Announces Preliminary Unaudited Fourth Quarter 2023 Financial Results
-
Cohen & Company Reports Fourth Quarter & Full Year 2023 Financial Results
-
Amplify Energy Announces Fourth Quarter and Full-Year 2023 Results, Year-End 2023 Proved Reserves and Full-Year 2024 Guidance
-
Five Below, Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Earnings Release and Conference Call Date
-
Lulus Reports Fourth Quarter and Fiscal Year 2023 Results
-
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results
-
SuRo Capital Corp. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on Wednesday, March 13, 2024
-
Phunware to Participate in the 36th Annual ROTH Conference
-
AIU Announces Receipt of NYSE Non-compliance Letter Regarding ADS Trading Price
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
